<DOC>
	<DOCNO>NCT00304590</DOCNO>
	<brief_summary>This clinical study conduct multiple site determine activity , safety , tolerability XL999 give weekly patient relapse refractory multiple myeloma . XL999 small molecule inhibitor cellular factor include VEGFR , PDGFR , FGFR may involve multiple myeloma .</brief_summary>
	<brief_title>Study XL999 Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Males female diagnosis MM base bone marrow aspirate biopsy ≥10 % plasma cell ( biopsy tissue monoclonal plasma cell ) , M protein level serum urine , evidence end organ tissue impairment ( hypercalcemia , renal insufficiency , anemia , lytic bone lesion ) , define The International Myeloma Working Group Criteria ( 2003 ) , initial diagnosis ( initiation chemotherapy ) Measurable disease define serum and/or urine M component electrophoresis Refractory relapse 2 prior treatment regimen ( chemotherapy , biologic hematopoietic stem cell transplantation ) Concurrent therapy bisphosphonate acceptable ECOG performance status 0 1 Life expectancy ≥3 month Adequate liver function No malignancy within 5 year Signed informed consent Nonsecretory myeloma , monoclonal gammopathy uncertain significance ( MGUS ) , smolder myeloma Anticancer therapy include chemotherapeutic , biologic , investigational agent , include dexamethasone , within 30 day XL999 treatment Hematopoietic stem cell transplantation within previous 6 week Radiation ≥33 % bone marrow within 30 day XL999 treatment Subject recover grade ≤1 within 10 % baseline adverse event due investigational chemotherapeutic drug administer &gt; 30 prior study enrollment Uncontrolled and/or intercurrent illness Pregnant breastfeeding female Known HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>